EQUIPO DE ENFERMEDADES DEGENERATIVAS CBM – CARLOS DOTTI

‘Nanoparticle-based, brain-exclusive, delivery of p38 MAPK inhibitors for the treatment of Alzheimer’s disease’

Grants for research teams

Biomedicine

neurodegenerative diseases

2015

The final objective of this work is to utilize nanobiotechnology for brain‐only inhibition of p38MAPK activity as therapeutic approach against Alzheimer’s disease (AD).